Zhaoke Ophthalmology Limited has reached a memorandum of agreement (MOA) with Fareva, a French contract manufacturing organization, under which Zhaoke will become the recommended partner for Fareva’s customers looking to manufacture pharmaceutical products in China.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “At Zhaoke, our mission is to deliver high-quality ophthalmic treatments to patients worldwide. We are honored that both our R&D and world-class manufacturing capabilities have been recognized by Fareva, further validating our global standards. Developing drugs requires excellence at every stage – especially in R&D and manufacturing, where science becomes reality. Our state-of-the-art facility in Nansha, Guangzhou, China represents this commitment. Moreover, this strategic partnership also marks a significant step in our global expansion strategy. By joining forces with premier partners, we accelerate our ability to address unmet needs in eye care and expand access to cutting-edge therapies across key international markets.”